Differences in Clinical outcomes between Non-Obese Hispanic and Asian populations Who have Hyperlipidemia

IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY Journal of clinical lipidology Pub Date : 2024-07-01 DOI:10.1016/j.jacl.2024.04.097
Leonid Khokhlov MD, Gehna Kishore MD, Godbless Ajenaghughrure MD, Kamal Shemisa MD, Sindhu Kishore MD
{"title":"Differences in Clinical outcomes between Non-Obese Hispanic and Asian populations Who have Hyperlipidemia","authors":"Leonid Khokhlov MD,&nbsp;Gehna Kishore MD,&nbsp;Godbless Ajenaghughrure MD,&nbsp;Kamal Shemisa MD,&nbsp;Sindhu Kishore MD","doi":"10.1016/j.jacl.2024.04.097","DOIUrl":null,"url":null,"abstract":"<div><h3>Background/Synopsis</h3><p>Hyperlipidemia (HLD) is a metabolic disease that is closely linked with ethnicity. There is limited data on its outcomes in different racial groups. Treating HLD will reduce the risk of atherosclerotic cardiovascular disease.</p></div><div><h3>Objective/Purpose</h3><p>The purpose of this study is to compare differences in clinical outcomes in non-obese Hispanic and Asian populations with HLD.</p></div><div><h3>Methods</h3><p>Conducted as an observational study, it utilized data from the National Inpatient Sample from 2017 to 2020 focusing on non-obese adults over 18 years, with a BMI &lt;30 kg/m<sup>2</sup>, and HLD diagnosis, excluding those under 18, obese or without HLD. Primary outcome was in-hospital mortality. Secondary outcomes were cardiogenic shock, cardiac arrest, GIB, mechanical ventilation, LOS, and total cost. Multivariable logistic and Poisson regression analyses determined the clinical outcomes, considering a p-value &lt;0.05 significant.</p></div><div><h3>Results</h3><p>Among 31,300,000 non-obese adults with HLD, 71.4% were Caucasians, 8.2% were Hispanics, 2.9% were Asians, and the remaining population belonged to other ethnicities. This study revealed higher rates in the Asians for conditions like anemia, DKA, HTN, pHTN, Afib, ACS, STEMI, AKI, stroke, and severe sepsis. Hispanics were seen to have a higher incidence of DM, HF, PVD, CKD, PE, and COPD. In terms of the primary outcome, Asians had more in-hospital mortality than the Hispanics but the results were not statistically significant. Asians were higher than the Hispanics in terms of the secondary outcomes in all aspects as seen in Table 1.</p></div><div><h3>Conclusions</h3><p>The findings undermine the importance of racial differences in such conditions and more in-depth studies are needed to extrapolate the gaps in care. Also, Asian population has been seen to have worse outcomes compared to all the major ethnical groups.</p></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"18 4","pages":"Pages e559-e560"},"PeriodicalIF":3.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1933287424001442","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/Synopsis

Hyperlipidemia (HLD) is a metabolic disease that is closely linked with ethnicity. There is limited data on its outcomes in different racial groups. Treating HLD will reduce the risk of atherosclerotic cardiovascular disease.

Objective/Purpose

The purpose of this study is to compare differences in clinical outcomes in non-obese Hispanic and Asian populations with HLD.

Methods

Conducted as an observational study, it utilized data from the National Inpatient Sample from 2017 to 2020 focusing on non-obese adults over 18 years, with a BMI <30 kg/m2, and HLD diagnosis, excluding those under 18, obese or without HLD. Primary outcome was in-hospital mortality. Secondary outcomes were cardiogenic shock, cardiac arrest, GIB, mechanical ventilation, LOS, and total cost. Multivariable logistic and Poisson regression analyses determined the clinical outcomes, considering a p-value <0.05 significant.

Results

Among 31,300,000 non-obese adults with HLD, 71.4% were Caucasians, 8.2% were Hispanics, 2.9% were Asians, and the remaining population belonged to other ethnicities. This study revealed higher rates in the Asians for conditions like anemia, DKA, HTN, pHTN, Afib, ACS, STEMI, AKI, stroke, and severe sepsis. Hispanics were seen to have a higher incidence of DM, HF, PVD, CKD, PE, and COPD. In terms of the primary outcome, Asians had more in-hospital mortality than the Hispanics but the results were not statistically significant. Asians were higher than the Hispanics in terms of the secondary outcomes in all aspects as seen in Table 1.

Conclusions

The findings undermine the importance of racial differences in such conditions and more in-depth studies are needed to extrapolate the gaps in care. Also, Asian population has been seen to have worse outcomes compared to all the major ethnical groups.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
非肥胖西班牙裔和亚裔高脂血症患者的临床结果差异
背景/简介高脂血症(HLD)是一种与种族密切相关的代谢性疾病。关于不同种族群体的高脂血症治疗效果的数据十分有限。本研究的目的是比较非肥胖的西班牙裔和亚裔 HLD 患者的临床结局差异。方法作为一项观察性研究,本研究利用了 2017 年至 2020 年全国住院患者样本数据,重点关注 18 岁以上、体重指数为 30 kg/m2 且确诊为 HLD 的非肥胖成人,不包括 18 岁以下、肥胖或无 HLD 的患者。主要结果为院内死亡率。次要结果为心源性休克、心脏骤停、GIB、机械通气、住院时间和总费用。结果在 31,300,000 名患有 HLD 的非肥胖成人中,71.4% 为白种人,8.2% 为西班牙裔人,2.9% 为亚洲人,其余为其他种族。这项研究显示,亚洲人中贫血、DKA、高血压、pHTN、阿非布、ACS、STEMI、AKI、中风和严重败血症等疾病的发病率较高。西班牙裔的糖尿病、高血压、心血管疾病、慢性肾脏病、心肌梗塞和慢性阻塞性肺病发病率较高。在主要结果方面,亚裔的院内死亡率高于西班牙裔,但结果并无统计学意义。如表 1 所示,亚裔在各方面的次要结果中均高于西班牙裔。结论这些研究结果削弱了种族差异在此类疾病中的重要性,需要进行更深入的研究来推断护理方面的差距。此外,与所有主要种族群体相比,亚裔的治疗效果更差。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.00
自引率
6.80%
发文量
209
审稿时长
49 days
期刊介绍: Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
期刊最新文献
Burden of atherogenic lipids and association with cardiac allograft vasculopathy in heart transplant recipients. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. Identification and functional analysis of novel homozygous LMF1 variants in severe hypertriglyceridemia. Falsely elevated triglyceride and lipase levels due to hyperglycerolemia in a burn patient treated with topical silver sulfadiazine. Complex dyslipidemia induced by Lorlatinib therapy: A case study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1